Scientists used genetic sequencing to discover that the vaccine used in the RV144 HIV vaccine trial, involving 16,000 men and women in Thailand, did offer some protection against certain HIV viruses. The results were published Sept. 10 in the online edition of Nature.
James Mullins, UW professor of microbiology, medicine and laboratory medicine, leads one of the two laboratories that did genetic analyses of the virus. He said the study proved that an HIV vaccine is within reach.
“This study showed that a vaccine is possible,” Mullins said. “However, in order to be generally useful, we need to enhance its potency over that achieved in the Thai trial.”